000			03453nam a22003975i 4500
001			293154
003			MX-SnUAN
005			20160429155055.0
007			cr nn 008mamaa
008			150903s2013 sz | o |||| 0|eng d
020			_a9783034806640 _99783034806640
024	7		_a10.1007/9783034806640 _2doi
035			_avtls000345370
039		9	_a201509030412 _bVLOAD _c201405050320 _dVLOAD _y201402061334 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC261-271
100	1		_aMaximov, Philipp Y. _eautor _9325522
245	1	0	_aTamoxifen : _bPioneering Medicine in Breast Cancer / _cby Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan.
264		1	_aBasel : _bSpringer Basel : _bImprint: Springer, _c2013.
300			_axxii, 199 páginas 54 ilustraciones, 32 ilustraciones en color. _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aMilestones in Drug Therapy
500			_aSpringer eBooks
505	0		_aDiscovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens -- Tamoxifen Goes Forward Alone -- Metabolites of Tamoxifen as the Basis of Drug Development -- Adjuvant Therapy – The Breakthrough -- The Wisconsin Story in the 1980’s: Discovery of Target Site Specific Estrogen Action -- Carcinogenesis and Tamoxifen -- Chemoprevention: Cinderella waiting for the ball -- Tamoxifen and Raloxifene head to head: The STAR TRIAL -- Acquired resistance to Tamoxifen: back to the beginning -- The legacy of Tamoxifen -- Appendix: Four decades of discovery in breast cancer research and treatment – an interview with V. Craig Jordan by Marc Poirot -- Selected Awards that Recognize the Contribution of Tamoxifen and Raloxifene to Medicine.
520			_aTamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aMcDaniel, Russell E. _eautor _9325523
700	1		_aJordan, V. Craig. _eautor _9325524
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9783034806633
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-0348-0664-0 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c293154 _d293154